Summary
This genetic meta-analysis of 112,772 participants assessed whether lowering LDL cholesterol via PCSK9 inhibition carries similar cardiovascular and metabolic effects to statin-mediated HMGCR inhibition. Variants in both genes showed nearly identical protective effects on cardiovascular risk (OR 0.81 per 10 mg/dL LDL reduction) but were associated with increased diabetes risk (OR 1.11–1.13), an effect limited to individuals with impaired fasting glucose. The findings suggest PCSK9 inhibition may offer comparable cardiovascular benefit to statins but warrant careful monitoring for metabolic consequences.
UK applicability
These findings are directly relevant to UK clinical practice and cardiovascular disease prevention policy, as PCSK9 inhibitors are now licensed and used in the NHS for high-risk patients. The identification of a potential diabetes risk signal, even if modest and confined to those with glucose dysregulation, should inform prescribing guidelines and patient stratification strategies in UK primary and secondary care.
Key measures
Odds ratios for cardiovascular events and diabetes per 10 mg/dL (0.26 mmol/L) decrease in LDL cholesterol; genetic scores from PCSK9 and HMGCR variants; 14,120 cardiovascular events and 10,635 diabetes cases across 112,772 participants
Outcomes reported
The study examined the effect of genetic variants in PCSK9 and HMGCR genes on cardiovascular disease and diabetes risk across 112,772 participants from 14 studies, using genetic variants as natural experiments to assess the impact of LDL cholesterol lowering. Researchers compared odds ratios for cardiovascular events and diabetes incidence per 10 mg/dL decrease in LDL cholesterol mediated by each gene variant.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.